Meier and coauthors found that topotecan improved progression-free and overall survival compared with treosulfan in patients with recurrent ovarian cancer following platinum and taxane-based therapy.

In total, 28 patients received farletuzumab and 46 patients received farletuzumab in combination with standard platinum and taxane chemotherapy. The researchers reported preliminary data from 41 ...